NantOmics specializes in precision medicine by utilizing an integrated panomic approach to assess molecular alterations in cancer patients' tumors. Their technology combines whole genome sequencing, RNA sequencing, and quantitative proteomics to create a comprehensive molecular profile for each patient. This multi-faceted analysis allows for the identification of tumor-specific alterations at the DNA level, validation of these mutations through RNA sequencing, and measurement of clinically significant protein levels. By integrating these data points, NantOmics can pinpoint disrupted cellular pathways that are unique to each patient's cancer, thereby enhancing the understanding of the disease and informing personalized treatment strategies.

The company's proprietary analytical platform plays a crucial role in delivering actionable intelligence for cancer management. It leverages a vast knowledge database that includes hundreds of oncogenes and thousands of cellular pathways to identify genomic and proteomic alterations with significant clinical relevance. This information is then matched with targeted therapies that may be effective against the specific alterations found in a patient's tumor. By providing molecularly driven decision support at the point of care, NantOmics aims to improve treatment outcomes and facilitate personalized management of cancer patients.

United States

NantOmics is a molecular diagnostic firm that develops cloud-based molecular profiling tools that helps to guide cancer patients.

OncoPlexDx(NantOmics)

Company Details